A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...

The GLP-1 moment signals how quickly a high-demand therapy can upend established care patterns—and how similar innovations may emerge in the years ahead.

More than one-quarter of adults aged 25 to 64 years from 99 countries are eligible to receive a GLP-1 receptor agonist.

Bariatric surgery and GLP-1 drugs are associated with reductions in fat mass and a shift in body composition toward a higher ...

Young, affluent and health‑driven, GLP‑1 users are reshaping food retail with demand for protein‑rich, nutrient‑dense and convenient meals.